The major finding of this study was that by using iTRAQ, we were able to identify three proteins: putative hydroxypyruvate isomerase (HYI), eukaryotic translation initiation factor 4H (eIF4H), and RNA binding motif 8A (RBM8A), which were validated by Western blot, as the potential biomarkers for paroxetine treatment response in MDD patients. The gene discussed is RBM8A; the disease is major depressive disorder.